Insights

ViewPoints Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep&amp Viral RNA UM Kit

  • by

In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep&amp Viral RNA UM Kit. Shots: QIAGEN to launch the QIAprep&amp Viral RNA UM Kit, designed to simplify and accelerate PCR swab… Read More »ViewPoints Interview: QIAGEN’s Kai te Kaat Shares Insights on QIAprep&amp Viral RNA UM Kit

Insights+ Interview: Paige’s CEO, Leo Grady Shares Insights on its Series B Funding and the FDA’s 510(k) Clearance for FullFocus Viewer

  • by

Paige is a global digital pathology founded in 2017 by Thomas Fuchs, Dr. Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The company involves computational pathology products that are targeted for patients and their care teams for effective, more informed treatment decisions. Paige has… Read More »Insights+ Interview: Paige’s CEO, Leo Grady Shares Insights on its Series B Funding and the FDA’s 510(k) Clearance for FullFocus Viewer

Customer Success: Formulary Management

  • by

In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day Patent Challenge Exclusivity Expirations Anticipate… The post Customer Success: Formulary Management appeared first on DrugPatentWatch – Make Better Decisions.

Automated Reports and Custom Dashboards

  • by

Let DrugPatentWatch build custom dashboards and reports to take the load off of your team. We can ensure the production of accurate, objective, and timely intelligence to help you quickly… The post Automated Reports and Custom Dashboards appeared first on DrugPatentWatch – Make Better Decisions.

Drug repurposing patent documents vs peer review: patent information comes more than 600 days earlier on average

  • by

This article was originally published by Hermann Mucke & Peter Mucke in Future Drug Discovery under a Attribution-NonCommercial-NoDerivatives 4.0 Unported License. https://doi.org/10.4155/fdd-2020-0001. Drug developers require access to scientific information in… The post Drug repurposing patent documents vs peer review: patent information comes more than 600… Read More »Drug repurposing patent documents vs peer review: patent information comes more than 600 days earlier on average

244 Drug Patents With Claims Containing “consisting essentially of” may be Unenforceable

  • by

In a recent court ruling, the U.S. Court of Appeals for the Federal Circuit (CAFC) denied a petition to rehear arguments regarding the invalidity of patent claims containing the phrase… The post 244 Drug Patents With Claims Containing “consisting essentially of” may be Unenforceable appeared… Read More »244 Drug Patents With Claims Containing “consisting essentially of” may be Unenforceable

Customer Success: How do we identify generic entrants before they get FDA approval?

  • by

DrugPatentWatch can help identify generic entrants at the earliest stages Many clients come to DrugPatentWatch seeking to identify generic entrants well before they launch. CDMOs, equipment manufacturers, regulatory consultants, and… The post Customer Success: How do we identify generic entrants before they get FDA approval?… Read More »Customer Success: How do we identify generic entrants before they get FDA approval?

DrugPatentWatch Headlines Swissbiotech Annual Report

  • by

The latest Swiss Biotech annual report focuses on the theme of shaping change. Change is a theme DrugPatentWatch is very familiar with — whether it is a matter of tracking… The post DrugPatentWatch Headlines Swissbiotech Annual Report appeared first on DrugPatentWatch – Make Better Decisions.

Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection

  • by

This article was originally published by Christopher M. Holman* in Intellectual Property Watch under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Despite the important role of intellectual property rights in… The post Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection appeared first on… Read More »Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection

The Influence of Emerging Markets on the Pharmaceutical Industry

  • by

This paper was originally published by  Maya Tannoury and Zouhair Attieh in Current Therapeutic Research under a creative commons license. Abstract Emerging markets represent an exceptional opportunity for the pharmaceutical… The post The Influence of Emerging Markets on the Pharmaceutical Industry appeared first on DrugPatentWatch… Read More »The Influence of Emerging Markets on the Pharmaceutical Industry